Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
What started as a therapeutic class focused primarily on type 2 diabetes management has now evolved into a powerful, sustained, evidence-based solution for obesity and weight reduction- a disease in its own right
It represents the first dual incretin receptor agonist approved by the Medicines and Healthcare products Regulatory Agency (MHRA)
Board Certified Dermatologist
Sanofi : While having a presence in the diabetes market, its direct contribution to the GLP-1 receptor agonist segment in Australia might be comparatively smaller than Novo Nordisk or Eli Lilly
If you really want long-lasting weight loss, youll need to pair the medication with healthy lifestyle changes like diet and exercise
US$ 23.02
US$ 24.67
US$ 29.49
